203 related articles for article (PubMed ID: 31638179)
1. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer.
Magic Z; Sandström J; Perez-Tenorio G
Int J Oncol; 2019 Dec; 55(6):1275-1286. PubMed ID: 31638179
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Ann Oncol; 2007 Mar; 18(3):485-90. PubMed ID: 17108150
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Gynecol Oncol; 2009 Jul; 114(1):84-8. PubMed ID: 19356789
[TBL] [Abstract][Full Text] [Related]
4. Low concentrations of TNF-α promote osteogenic differentiation via activation of the ephrinB2-EphB4 signalling pathway.
Wang L; Zhang J; Wang C; Qi Y; Du M; Liu W; Yang C; Yang P
Cell Prolif; 2017 Feb; 50(1):. PubMed ID: 27726217
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
6. The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme.
Bhatia S; Bukkapatnam S; Van Court B; Phan A; Oweida A; Gadwa J; Mueller AC; Piper M; Darragh L; Nguyen D; Gilani A; Knitz M; Bickett T; Green A; Venkataraman S; Vibhakar R; Cittelly D; Karam SD
Mol Carcinog; 2020 Sep; 59(9):1064-1075. PubMed ID: 32567728
[TBL] [Abstract][Full Text] [Related]
7. Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of the EphrinB2-EphB4 ratio in pediatric cerebral arteriovenous malformations is associated with endothelial cell dysfunction in vitro and functions as a novel noninvasive biomarker in patients.
Fehnel KP; Penn DL; Duggins-Warf M; Gruber M; Pineda S; Sesen J; Moses-Gardner A; Shah N; Driscoll J; Zurakowski D; Orbach DB; Smith ER
Exp Mol Med; 2020 Apr; 52(4):658-671. PubMed ID: 32286515
[TBL] [Abstract][Full Text] [Related]
9. Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment.
Das A; Shergill U; Thakur L; Sinha S; Urrutia R; Mukhopadhyay D; Shah VH
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G908-15. PubMed ID: 20338920
[TBL] [Abstract][Full Text] [Related]
10. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
11. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Tu Y; He S; Fu J; Li G; Xu R; Lu H; Deng J
Clin Transl Oncol; 2012 Mar; 14(3):214-20. PubMed ID: 22374425
[TBL] [Abstract][Full Text] [Related]
12. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Br J Cancer; 2008 Feb; 98(4):845-51. PubMed ID: 18231102
[TBL] [Abstract][Full Text] [Related]
15. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
16. Effect of EphB4/EphrinB2 reverse signal on angiogenesis induced by Xuefu Zhuyu Capsule () containing serum in human microvascular endothelial cell 1.
Zhang JS; Wang YZ; Hu YQ; Lin F; Gao D; Song J; Kaptchuk TJ; Chen KJ
Chin J Integr Med; 2016 Aug; 22(8):605-10. PubMed ID: 27299459
[TBL] [Abstract][Full Text] [Related]
17. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
Kertesz N; Krasnoperov V; Reddy R; Leshanski L; Kumar SR; Zozulya S; Gill PS
Blood; 2006 Mar; 107(6):2330-8. PubMed ID: 16322467
[TBL] [Abstract][Full Text] [Related]
18. The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Yavrouian EJ; Sinha UK; Rice DH; Salam MT; Gill PS; Masood R
Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):985-91. PubMed ID: 18794445
[TBL] [Abstract][Full Text] [Related]
19. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Huang X; Yamada Y; Kidoya H; Naito H; Nagahama Y; Kong L; Katoh SY; Li WL; Ueno M; Takakura N
Cancer Res; 2007 Oct; 67(20):9800-8. PubMed ID: 17942910
[TBL] [Abstract][Full Text] [Related]
20. Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro.
He S; Kumar SR; Zhou P; Krasnoperov V; Ryan SJ; Gill PS; Hinton DR
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):543-52. PubMed ID: 19696168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
